abpi scotland: medicines in scotland. membership body of the pharmaceutical industry – statutory...
TRANSCRIPT
ABPI Scotland:Medicines in Scotland
•Membership body of the Pharmaceutical Industry – statutory negotiating body
•Represents majority of research based companies
•Members supply over 90% of medicines to the NHS
•2/3rd of all research and development of new medicines is undertaken by member companies
•ABPI Code of Practice - administered by
PMCPA
http://www.pmcpa.org.uk/Pages/default.aspx
What is ABPI?
2
•The pharmaceutical industry globally invests more in research and development than any other industry – £12.1 million every day.
•The pharmaceutical industry employs around 25,000 people in R&D in the UK (Business Enterprise Research and Development (2008, 2009, 2010) 2010 released Nov 2011 – Office for National Statistics (ONS).
Investment
3
4
•Uptake and innovation
•Pricing: is it a barrier to uptake?
•Clinical research: are we under threat?
•Who we are and how we operate
5
ABPI: Key issues...
•Uptake and innovation
– Low and slow
6
ABPI: Key issues...
Market share of innovative products in the UK is behind European peers and deteriorating
(1) IMS Health World Review Analyst, 2010 (2) OHE analysis 2012
Market share for products -brands and generics- launched in the past 5 years by value (%)(1)
NICE’s ~40% rejection rate and NICE ‘blight’ lead to delays and limited access as well as poor performance in innovation uptake(2)
7
Branded medicines launched in the past 5 years are expected to account for 5% of spend only by 2015, similar to previous
years’ levels
Uptake of new medicines in Scotland (OHE stats)
8
Scottish Government recognised there is a problem:
o CEL 17 (and follow-up CMO)
o Statement of Intent
o New medicines review (recently announced)
Scottish Parliament has recognised there is a problem:
o Public Petitions Committee inquiry
o Health & Sport Committee Inquiry (ongoing)
9
Uptake of new medicines in Scotland...
•Pricing: is it a barrier to uptake?
10
ABPI: Key issues...
Overall, UK spending on medicines as a percentage of GDP (developed countries)…
(1) IMS Health World Review Analyst 2012. OECD Health Database. All data accessed March 2012
Spending on medicines as a percentage of GDP in various countries in 2011(1)
11
If Spain cut down pharmaceutical spend by 20%, the proportion of GDP would be 1.2%, i.e. still higher than in the
UK’s
The UK has severe uptake issues in critical therapy areas
12
The UK has the lowest per capita spend in cancer medicines launched in the past 5 years
(1) IMS Midas 2006
£
Spend per capita on cancer medicines launched in the previous 5 years in Europe (£)(1)
Branded pharmaceutical prices are amongst the lowest in developed countries
2003 2004 2007 2008 2010 2011USA 190 USA 176 USA 183 USA 252 USA 281 USA 331
Germany 102 Germany 106 Germany 113 Germany 142 Germany 155 Germany 153
UK 100 UK 100 Ireland 112 Ireland 134 Australia 139 Australia 143
Finland 98 Ireland 99 Sweden 105 Belgium 122 Ireland 133 Sweden 134
Austria 94 Finland 96 Belgium 101 Finland 119 Sweden 130 Belgium 123
Netherlands 93 Austria 94 UK 100 Sweden 116 Belgium 122 Ireland 123
Belgium 91 Netherlands 92 Finland 99 Netherlands 115 Austria 117 Netherlands 117
France 91 Belgium 90 Netherlands 99 Austria 111 Italy 113 Austria 115
Italy 90 Italy 90 Austria 96 Spain 109 Spain 106 France 104
Spain 81 France 84 Australia 94 France 108 Finland 105 Finland 103
Australia - Spain 80 France 92 Italy 101 France 104 Italy 101
Ireland - Australia - Spain 88 UK 100 UK 100 Spain 101
Sweden - Sweden - Italy 83 Australia 94 Netherlands - UK 100
(1) OHE, 11th Report (2004-2010); 5th Report (2000 - 2003); 2011: OHE calculations based on IMS and PCA data. Note: blank cell = Not availableNotes: Table includes the years prior to PPRS negotiations (2003/2004; 2007/2008) as well as for 2010 and 2011Exchange rate used: Average of Q4 of every year.
Position of the UK in the ranking of branded pharmaceutical prices by year(1)
13In a recent report (September 2012) The European Commission has indicated that the
UK is a highly efficient medicines market
•Total medicines bill for NHSScotland is projected to increase by 2.9% - 3.9% (£1.37bn - £1.43bn)
•Branded medicines bill for NHSScotland is projected to increase by 0.5% - 1.5% (£0.99bn – £1.03bn)
14
Betweeen 2011 and 2015 (at list prices -
OHE)...
•Clinical research: are we under threat?
15
ABPI: Key issues...
While the pharma sector contributes 1 in 2 R&D pounds in the UK(1), it is in decline
% o
f g
lob
al s
ales
of
lead
ing
100
m
edic
ines
by
cou
ntr
y o
f o
rig
in
National origin of leading 100 global medicines by sales 2004–2011 (2)
16
Twelve major pharmaceutical site closures between 1996 and 2012(4)
(1) ONS UK Business Enterprise Research and Development, 2009(2) Department of Health, MISG, Pharmaceutical Industry: Competitiveness and Performance Indicators 2009(3) Centre for Medicines Research (www.cmr.org); Global Clinical Performance Metrics Database; Kinapse report(4) ABPI analysis
UK Global Share of patients in clinical trials 2000 – 2010(3)
0%
1%
2%
3%
4%
5%
6%
7%
8%
2010
1.4%
20062000
6%
2%
-77%
•Evidence given to the Health & Sport Committee inquiry into new medicines from:
–a group of 17 oncologists–Oral evidence of a further oncologist–Cancer Research UK:
“The UK’s lower rate of uptake for new cancer drugs may be damaging to our ability to design and run internationally competitive studies. If very few patients can get licensed drugs that are the standard of care outside the UK, this could lead to fewer industry-supported trials being conducted in the UK”
17
Don’t just take our word for it...
A changing relationship
The industry position on trial registry and the
publication of resultsABPI Code of Practice 2012
•all trials must be registered within 21 days of the initiation of patient enrolment
• results positive or negative, must be published within one year of marketing authorisation
Where will we be in 2016?
On transparency of financial relationships
•Payments to health professionals across Europe will be publicly declared
•Medical Education Grants to Healthcare Organisations will be publicly disclosed
•All payments to patient organisations will be publically disclosed
On access to clinical trial and safety information
•All trials are registered
•All results published within one year of marketing authorisation
•Results from past trials accessible via the EMA criteria
•Proactive publication of unprecedented levels of safety data for all marketed medicines in the EU
The future…
21
•Harder and more expensive to develop medicines – no more blockbusters…
•Personalised medicines…
•Less money, more patients…
–Health & social care integration
–Long term conditions
–Move away from acute care
The future…
23
